- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06700447
Bescherming tegen desinformatie over HIV-vaccins bij adolescente meisjes en jonge vrouwen in Zuid-Afrika (PROTECT)
Adolescent girls and young women (AGYW) between the ages of 15-29 years continue to bear the brunt of Human Immunodeficiency Virus (HIV) infections in South Africa despite progress recorded in prevention and treatment programmes. The ongoing susceptibility of young women to HIV infection and the sub-optimal uptake of prevention options such as Pre-Exposure Prophylaxis (PrEP) that are highly effective creates a need for an HIV vaccine to benefit populations at substantial risk of HIV infection. However, lessons from previous vaccine studies and the recent COVID-19 vaccine have highlighted significant barriers to vaccine uptake, such as widespread misinformation and vaccine hesitancy. These challenges threaten the successful implementation of a future HIV vaccine. Building on these insights, this study will utilise psychological inoculation theory to develop and evaluate HIV vaccine messages among adolescent girls and young women. Primary objective: To compare changes in intentions to receive HIV vaccine following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.
Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about the HIV vaccine in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Johannesburg, Zuid-Afrika
- Health Economics and Epidemiology Research Office, University of the Witwatersrand
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Female
- Age 18-29 years
- Self-reported history of sexual activity in the past 12 months
- Self-reported HIV-negative status or unknown HIV status at enrolment
- Willing and able to provide written informed consent
- Able to read and understand English
Exclusion Criteria:
- Unwilling or unable to provide consent for study participation.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Control
Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study. |
Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study. |
|
Ander: Enhanced inoculation message
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. |
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
HIV Vaccine Intention, at the End of the Baseline Assessment
Tijdsspanne: At the end of the baseline assessment
|
Intention to get the HIV vaccine, measured after inoculation intervention and misinformation exposure The intention to get the vaccine will be measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine. |
At the end of the baseline assessment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
HIV Vaccine Intention, Follow-up
Tijdsspanne: 2-4 weeks
|
Intention to get the HIV vaccine, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine. |
2-4 weeks
|
|
Recommend to Friends, at the End of the Baseline Assessment
Tijdsspanne: At the end of the baseline assessment
|
Intention to recommend the HIV vaccine to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend. |
At the end of the baseline assessment
|
|
Recommend to Friends, Follow-up
Tijdsspanne: 2-4 weeks
|
Intention to recommend the HIV vaccine to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend. |
2-4 weeks
|
|
Credibility of Inoculated Exposure #1
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #2
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #3
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #3 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #4
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #4 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #5
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #5 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #6
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #6 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #1
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #2
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #3
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #3 made the participants anxious or nervous about the HIV vaccine. TThey were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #4
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #4 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #5
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #5 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #6
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #6 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #1
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #7
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #7 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #3
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #3 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #4
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #4 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #5
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #5 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #6
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #6 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #1, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of Inoculated Exposure #2, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Shareability of Inoculated Exposure #1, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of Inoculated Exposure #2, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Anxiousness of Inoculated Exposure #1, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of Inoculated Exposure #2, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #12, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #12 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #8, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #8 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #9, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #9 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #10, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #10 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #11, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #11 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Anxiousness o of New Claims, Exposure #12, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #12 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Claim #8, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #8 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #9, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #9 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #10, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #10 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #11, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #11 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #12, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #12 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #8, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #8 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #9, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #9 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #10, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #10 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #11, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #11 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Credibility of Inoculated Exposure #7
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #7 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #7
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #7 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #2
Tijdsspanne: At the end of the baseline assessment
|
Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Credibility of New Claims, Exposure #13, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #13 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #13, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #13 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #13, Follow-up
Tijdsspanne: 2-4 weeks
|
Extent to which claim #13 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1R01MH132401 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The investigators are still determining the data sharing plan and if we will be sharing IPD yet
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .